Summary & Overview
Wound Debridements for Injuries with CC: Inpatient Reimbursement Overview
DRG 902 encompasses inpatient admissions for wound debridement procedures for traumatic injuries when a Complication or Comorbidity is present. This Diagnosis-Related Group groups operative wound care with associated medical complexity, which affects Medicare inpatient reimbursement by reflecting higher expected resource use.
DRG 902 Overview
DRG 902 covers inpatient admissions for wound debridements related to traumatic injuries when a Complication or Comorbidity is present. Typical cases include surgical removal of devitalized tissue from traumatic wounds, burns, or contaminated lacerations that require inpatient care beyond simple bedside management. This Diagnosis-Related Group affects Medicare payment by grouping resource use for operative wound care with the presence of a Complication or Comorbidity, which influences relative reimbursement compared with non-Complication or Comorbidity cases. Accurate coding of procedure and comorbid conditions determines assignment to this Diagnosis-Related Group for inpatient reimbursement.
Clinical Trials
- Acute operative and nonoperative wound management trials: randomized or controlled studies comparing different immediate debridement strategies (e.g., surgical tangential debridement versus staged/sharp debridement or hydrosurgical systems) and adjunctive intraoperative approaches for traumatic and complex soft-tissue wounds with a complication or comorbidity. These studies enroll hospitalized patients presenting with traumatic lacerations, avulsions, burns extension, or infected wounds that meet criteria for debridement with a CC, and they assess short‑term outcomes such as time to viable granulation tissue, need for repeat debridement, rates of surgical site infection, length of stay, and early limb salvage. Results inform operative decision‑making, resource utilization in the acute inpatient episode, and payer concerns about repeat procedures and hospitalization duration.
- Comparative effectiveness and infection‑prevention studies of adjunctive wound therapies: pragmatic trials or cohort studies evaluating the addition of topical antiseptics, negative-pressure wound therapy, antimicrobial dressings, or systemic antibiotic stewardship protocols in patients undergoing debridement for injury‑related wounds with comorbid conditions (for example diabetes, peripheral vascular disease, or immunosuppression). These trials focus on heterogeneous inpatient populations at higher risk of infection or delayed healing, measuring outcomes such as infection recurrence, need for reoperation, wound closure rates, and cost per episode of care. Findings are relevant to clinicians deciding perioperative and inpatient management and to payers assessing which adjuncts reduce downstream expenditures from readmissions, reoperations, and prolonged inpatient care.
- Post‑discharge functional recovery and utilization/outcomes studies: prospective observational cohorts or randomized transitional‑care interventions that follow patients after inpatient debridement for injuries with CC to evaluate wound healing trajectories, rehabilitation needs, home health utilization, readmission rates, and long‑term functional outcomes (including return to work and limb function). The population includes medically complex patients discharged after one or more debridements, often with requirements for staged closure, skin grafting, or prosthetic planning; studies assess predictors of poor outcomes and test care‑coordination models, telemedicine follow‑up, or structured wound‑care pathways. This research guides discharge planning, bundle payment designs, and payer strategies to reduce readmissions and optimize post‑acute costs while supporting durable functional recovery.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.